APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gene Therapy On Cardiovascular Disease

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Selected research

Market Analysis & Forecast

Global Gene Therapy On Cardiovascular Disease Market Analysis and Forecast 2026-2032

29 December 2025192 pages

Choose your research edition.

Industry ResearchGene Therapy On Cardiovascular Disease Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Gene Therapy On Cardiovascular Disease Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Gene Therapy On Cardiovascular Disease Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gene Therapy On Cardiovascular Disease Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Gene Therapy On Cardiovascular Disease Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.

Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.

Read the full market overview

Report Includes

This report presents an overview of global market for Gene Therapy On Cardiovascular Disease, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Gene Therapy On Cardiovascular Disease, also provides the revenue of main regions and countries. Of the upcoming market potential for Gene Therapy On Cardiovascular Disease, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Gene Therapy On Cardiovascular Disease revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Gene Therapy On Cardiovascular Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Gene Therapy On Cardiovascular Disease revenue, projected growth trends, production technology, application and end-user industry.

Gene Therapy On Cardiovascular Disease Segment by Company

Biogen

Novartis

Gilead Sciences

Sarepta Therapeutics

Alnylam Pharmaceuticals

Amgen

Spark Therapeutics

Akcea Therapeutics

bluebird bio

Sunway Biotech

SIBIONO

AnGes

Orchard Therapeutics

Human Stem Cells Institute

Gene Therapy On Cardiovascular Disease Segment by Type

Viral Gene Therapy

Non-Viral Gene Therapy

Gene Therapy On Cardiovascular Disease Segment by Application

Heart Disease

Vascular Disease

Gene Therapy On Cardiovascular Disease Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy On Cardiovascular Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy On Cardiovascular Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy On Cardiovascular Disease.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Gene Therapy On Cardiovascular Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Gene Therapy On Cardiovascular Disease company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapy On Cardiovascular Disease revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Viral Gene Therapy Major Player Table 3. Non-Viral Gene Therapy Major Player Table 4. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Heart Disease Major Player Table 6. Vascular Disease Major Player Table 7. Gene Therapy On Cardiovascular Disease Industry Trends Table 8. Gene Therapy On Cardiovascular Disease Industry Drivers Table 9. Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges Table 10. Gene Therapy On Cardiovascular Disease Industry Restraints Table 11. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global Gene Therapy On Cardiovascular Disease Market Size by Region (2021-2026) & (US$ Million) Table 13. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2021-2026) Table 14. Global Gene Therapy On Cardiovascular Disease Market Size by Region (2027-2032) & (US$ Million) Table 15. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2027-2032) Table 16. Global Gene Therapy On Cardiovascular Disease Revenue by Players (US$ Million) & (2021-2026) Table 17. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2021-2026) Table 18. Global Gene Therapy On Cardiovascular Disease Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global Gene Therapy On Cardiovascular Disease Key Players Headquarters & Area Served Table 20. Global Gene Therapy On Cardiovascular Disease Players, Product Type & Application Table 21. Global Gene Therapy On Cardiovascular Disease Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global Gene Therapy On Cardiovascular Disease by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global Gene Therapy On Cardiovascular Disease Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026) & (US$ Million) Table 26. Global Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032) & (US$ Million) Table 27. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2021-2026) Table 28. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2027-2032) Table 29. Global Gene Therapy On Cardiovascular Disease Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026) & (US$ Million) Table 31. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032) & (US$ Million) Table 32. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2021-2026) Table 33. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2027-2032) Table 34. Biogen Company Information Table 35. Biogen Business Overview Table 36. Biogen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Biogen Gene Therapy On Cardiovascular Disease Product Portfolio Table 38. Biogen Recent Development Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Novartis Gene Therapy On Cardiovascular Disease Product Portfolio Table 43. Novartis Recent Development Table 44. Gilead Sciences Company Information Table 45. Gilead Sciences Business Overview Table 46. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio Table 48. Gilead Sciences Recent Development Table 49. Sarepta Therapeutics Company Information Table 50. Sarepta Therapeutics Business Overview Table 51. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 53. Sarepta Therapeutics Recent Development Table 54. Alnylam Pharmaceuticals Company Information Table 55. Alnylam Pharmaceuticals Business Overview Table 56. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio Table 58. Alnylam Pharmaceuticals Recent Development Table 59. Amgen Company Information Table 60. Amgen Business Overview Table 61. Amgen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Amgen Gene Therapy On Cardiovascular Disease Product Portfolio Table 63. Amgen Recent Development Table 64. Spark Therapeutics Company Information Table 65. Spark Therapeutics Business Overview Table 66. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 68. Spark Therapeutics Recent Development Table 69. Akcea Therapeutics Company Information Table 70. Akcea Therapeutics Business Overview Table 71. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 73. Akcea Therapeutics Recent Development Table 74. bluebird bio Company Information Table 75. bluebird bio Business Overview Table 76. bluebird bio Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio Table 78. bluebird bio Recent Development Table 79. Sunway Biotech Company Information Table 80. Sunway Biotech Business Overview Table 81. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio Table 83. Sunway Biotech Recent Development Table 84. SIBIONO Company Information Table 85. SIBIONO Business Overview Table 86. SIBIONO Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio Table 88. SIBIONO Recent Development Table 89. AnGes Company Information Table 90. AnGes Business Overview Table 91. AnGes Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. AnGes Gene Therapy On Cardiovascular Disease Product Portfolio Table 93. AnGes Recent Development Table 94. Orchard Therapeutics Company Information Table 95. Orchard Therapeutics Business Overview Table 96. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio Table 98. Orchard Therapeutics Recent Development Table 99. Human Stem Cells Institute Company Information Table 100. Human Stem Cells Institute Business Overview Table 101. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio Table 103. Human Stem Cells Institute Recent Development Table 104. North America Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026) & (US$ Million) Table 105. North America Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032) & (US$ Million) Table 106. North America Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026) & (US$ Million) Table 107. North America Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032) & (US$ Million) Table 108. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026) & (US$ Million) Table 110. North America Gene Therapy On Cardiovascular Disease Revenue by Country (US$ Million) & (2027-2032) Table 111. Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026) & (US$ Million) Table 117. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (US$ Million) & (2027-2032) Table 118. China Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026) & (US$ Million) Table 119. China Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032) & (US$ Million) Table 120. China Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026) & (US$ Million) Table 121. China Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026) & (US$ Million) Table 123. Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032) & (US$ Million) Table 124. Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026) & (US$ Million) Table 125. Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia Gene Therapy On Cardiovascular Disease Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia Gene Therapy On Cardiovascular Disease Revenue by Region (US$ Million) & (2021-2026) Table 128. Asia Gene Therapy On Cardiovascular Disease Revenue by Region (US$ Million) & (2027-2032) Table 129. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026) & (US$ Million) Table 130. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032) & (US$ Million) Table 131. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026) & (US$ Million) Table 132. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032) & (US$ Million) Table 133. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026) & (US$ Million) Table 135. SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country (US$ Million) & (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. Gene Therapy On Cardiovascular Disease Image Figure 2. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gene Therapy On Cardiovascular Disease Market Size Share 2021 VS 2025 VS 2032 Figure 4. Viral Gene Therapy Image Figure 5. Non-Viral Gene Therapy Image Figure 6. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Gene Therapy On Cardiovascular Disease Market Size Share 2021 VS 2025 VS 2032 Figure 8. Heart Disease Image Figure 9. Vascular Disease Image Figure 10. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million) & (2021-2032) Figure 11. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Gene Therapy On Cardiovascular Disease Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global Gene Therapy On Cardiovascular Disease Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global Gene Therapy On Cardiovascular Disease Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gene Therapy On Cardiovascular Disease Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2021-2032) Figure 18. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2021-2032) Figure 21. North America Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032) Figure 23. North America Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032) Figure 24. North America Gene Therapy On Cardiovascular Disease Revenue Share by Country (2021-2032) Figure 25. United States Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032) Figure 30. Europe Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032) Figure 31. Europe Gene Therapy On Cardiovascular Disease Revenue Share by Country (2021-2032) Figure 32. Germany Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032) Figure 42. China Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032) Figure 43. Asia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032) Figure 45. Asia Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032) Figure 46. Asia Gene Therapy On Cardiovascular Disease Revenue Share by Region (2021-2032) Figure 47. Japan Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA Gene Therapy On Cardiovascular Disease Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032) Figure 55. SAMEA Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032) Figure 56. SAMEA Gene Therapy On Cardiovascular Disease Revenue Share by Country (2021-2032) Figure 57. Brazil Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt Gene Therapy On Cardiovascular Disease Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Viral Gene Therapy
  • Non-Viral Gene Therapy
Applications
  • Heart Disease
  • Vascular Disease
Companies covered
  • Biogen
  • Novartis
  • Gilead Sciences
  • Sarepta Therapeutics
  • Alnylam Pharmaceuticals
  • Amgen
  • Spark Therapeutics
  • Akcea Therapeutics
  • bluebird bio
  • Sunway Biotech
  • SIBIONO
  • AnGes
  • Orchard Therapeutics
  • Human Stem Cells Institute

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Gene Therapy On Cardiovascular Disease Market by Type
  3. 1.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Viral Gene Therapy
  5. 1.2.3 Non-Viral Gene Therapy
  6. 1.3 Gene Therapy On Cardiovascular Disease Market by Application
  7. 1.3.1 Global Gene Therapy On Cardiovascular Disease Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Heart Disease
  9. 1.3.3 Vascular Disease
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Gene Therapy On Cardiovascular Disease Market Dynamics
  1. 2.1 Gene Therapy On Cardiovascular Disease Industry Trends
  2. 2.2 Gene Therapy On Cardiovascular Disease Industry Drivers
  3. 2.3 Gene Therapy On Cardiovascular Disease Industry Opportunities and Challenges
  4. 2.4 Gene Therapy On Cardiovascular Disease Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Gene Therapy On Cardiovascular Disease Market Perspective (2021-2032)
  2. 3.2 Global Gene Therapy On Cardiovascular Disease Growth Trends by Region
  3. 3.2.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2021-2026)
  5. 3.2.3 Global Gene Therapy On Cardiovascular Disease Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Gene Therapy On Cardiovascular Disease Revenue by Players
  2. 4.1.1 Global Gene Therapy On Cardiovascular Disease Revenue by Players (2021-2026)
  3. 4.1.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Gene Therapy On Cardiovascular Disease Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Gene Therapy On Cardiovascular Disease Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Gene Therapy On Cardiovascular Disease Key Players Headquarters & Area Served
  7. 4.4 Global Gene Therapy On Cardiovascular Disease Players, Product Type & Application
  8. 4.5 Global Gene Therapy On Cardiovascular Disease Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Gene Therapy On Cardiovascular Disease Market CR5 and HHI
  11. 4.6.3 2025 Gene Therapy On Cardiovascular Disease Tier 1, Tier 2, and Tier 3
5 Gene Therapy On Cardiovascular Disease Market Size by Type
  1. 5.1 Global Gene Therapy On Cardiovascular Disease Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2032)
  3. 5.3 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2021-2032)
6 Gene Therapy On Cardiovascular Disease Market Size by Application
  1. 6.1 Global Gene Therapy On Cardiovascular Disease Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2032)
  3. 6.3 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biogen
  2. 7.1.1 Biogen Company Information
  3. 7.1.2 Biogen Business Overview
  4. 7.1.3 Biogen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biogen Gene Therapy On Cardiovascular Disease Product Portfolio
  6. 7.1.5 Biogen Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Gene Therapy On Cardiovascular Disease Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Gilead Sciences
  14. 7.3.1 Gilead Sciences Company Information
  15. 7.3.2 Gilead Sciences Business Overview
  16. 7.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Product Portfolio
  18. 7.3.5 Gilead Sciences Recent Developments
  19. 7.4 Sarepta Therapeutics
  20. 7.4.1 Sarepta Therapeutics Company Information
  21. 7.4.2 Sarepta Therapeutics Business Overview
  22. 7.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  24. 7.4.5 Sarepta Therapeutics Recent Developments
  25. 7.5 Alnylam Pharmaceuticals
  26. 7.5.1 Alnylam Pharmaceuticals Company Information
  27. 7.5.2 Alnylam Pharmaceuticals Business Overview
  28. 7.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product Portfolio
  30. 7.5.5 Alnylam Pharmaceuticals Recent Developments
  31. 7.6 Amgen
  32. 7.6.1 Amgen Company Information
  33. 7.6.2 Amgen Business Overview
  34. 7.6.3 Amgen Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Amgen Gene Therapy On Cardiovascular Disease Product Portfolio
  36. 7.6.5 Amgen Recent Developments
  37. 7.7 Spark Therapeutics
  38. 7.7.1 Spark Therapeutics Company Information
  39. 7.7.2 Spark Therapeutics Business Overview
  40. 7.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  42. 7.7.5 Spark Therapeutics Recent Developments
  43. 7.8 Akcea Therapeutics
  44. 7.8.1 Akcea Therapeutics Company Information
  45. 7.8.2 Akcea Therapeutics Business Overview
  46. 7.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  48. 7.8.5 Akcea Therapeutics Recent Developments
  49. 7.9 bluebird bio
  50. 7.9.1 bluebird bio Company Information
  51. 7.9.2 bluebird bio Business Overview
  52. 7.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  53. 7.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Product Portfolio
  54. 7.9.5 bluebird bio Recent Developments
  55. 7.10 Sunway Biotech
  56. 7.10.1 Sunway Biotech Company Information
  57. 7.10.2 Sunway Biotech Business Overview
  58. 7.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Product Portfolio
  60. 7.10.5 Sunway Biotech Recent Developments
  61. 7.11 SIBIONO
  62. 7.11.1 SIBIONO Company Information
  63. 7.11.2 SIBIONO Business Overview
  64. 7.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  65. 7.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Product Portfolio
  66. 7.11.5 SIBIONO Recent Developments
  67. 7.12 AnGes
  68. 7.12.1 AnGes Company Information
  69. 7.12.2 AnGes Business Overview
  70. 7.12.3 AnGes Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  71. 7.12.4 AnGes Gene Therapy On Cardiovascular Disease Product Portfolio
  72. 7.12.5 AnGes Recent Developments
  73. 7.13 Orchard Therapeutics
  74. 7.13.1 Orchard Therapeutics Company Information
  75. 7.13.2 Orchard Therapeutics Business Overview
  76. 7.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product Portfolio
  78. 7.13.5 Orchard Therapeutics Recent Developments
  79. 7.14 Human Stem Cells Institute
  80. 7.14.1 Human Stem Cells Institute Company Information
  81. 7.14.2 Human Stem Cells Institute Business Overview
  82. 7.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product Portfolio
  84. 7.14.5 Human Stem Cells Institute Recent Developments
8 North America
  1. 8.1 North America Gene Therapy On Cardiovascular Disease Revenue (2021-2032)
  2. 8.2 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2032)
  3. 8.2.1 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026)
  4. 8.2.2 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032)
  5. 8.3 North America Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032)
  6. 8.4 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2032)
  7. 8.4.1 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026)
  8. 8.4.2 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032)
  9. 8.5 North America Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032)
  10. 8.6 North America Gene Therapy On Cardiovascular Disease Revenue by Country
  11. 8.6.1 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026)
  13. 8.6.3 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Gene Therapy On Cardiovascular Disease Revenue (2021-2032)
  2. 9.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2032)
  3. 9.2.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026)
  4. 9.2.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032)
  5. 9.3 Europe Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032)
  6. 9.4 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2032)
  7. 9.4.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026)
  8. 9.4.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032)
  9. 9.5 Europe Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032)
  10. 9.6 Europe Gene Therapy On Cardiovascular Disease Revenue by Country
  11. 9.6.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026)
  13. 9.6.3 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Gene Therapy On Cardiovascular Disease Revenue (2021-2032)
  2. 10.2 China Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2032)
  3. 10.2.1 China Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026)
  4. 10.2.2 China Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032)
  5. 10.3 China Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032)
  6. 10.4 China Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2032)
  7. 10.4.1 China Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026)
  8. 10.4.2 China Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032)
  9. 10.5 China Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Gene Therapy On Cardiovascular Disease Revenue (2021-2032)
  2. 11.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2032)
  3. 11.2.1 Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026)
  4. 11.2.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032)
  5. 11.3 Asia Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032)
  6. 11.4 Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2032)
  7. 11.4.1 Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026)
  8. 11.4.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032)
  9. 11.5 Asia Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032)
  10. 11.6 Asia Gene Therapy On Cardiovascular Disease Revenue by Country
  11. 11.6.1 Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026)
  13. 11.6.3 Asia Gene Therapy On Cardiovascular Disease Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Gene Therapy On Cardiovascular Disease Revenue (2021-2032)
  2. 12.2 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Type (2027-2032)
  5. 12.3 SAMEA Gene Therapy On Cardiovascular Disease Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Application (2027-2032)
  9. 12.5 SAMEA Gene Therapy On Cardiovascular Disease Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country
  11. 12.6.1 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Gene Therapy On Cardiovascular Disease Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst